SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors - Yahoo Finance
BYSI Stock | USD 1.64 0.07 4.09% |
Under 54% of BeyondSpring's investor base is interested to short. The analysis of the overall investor sentiment regarding BeyondSpring suggests that many traders are impartial. BeyondSpring's investing sentiment shows overall attitude of investors towards BeyondSpring.
BeyondSpring |
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors Yahoo Finance
Read at news.google.com
BeyondSpring Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BeyondSpring can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BeyondSpring Fundamental Analysis
We analyze BeyondSpring's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeyondSpring using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeyondSpring based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
BeyondSpring is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
BeyondSpring Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeyondSpring stock to make a market-neutral strategy. Peer analysis of BeyondSpring could also be used in its relative valuation, which is a method of valuing BeyondSpring by comparing valuation metrics with similar companies.
Peers
BeyondSpring Related Equities
ARMP | Armata Pharmaceuticals | 4.29 | ||||
ADTX | Aditxt | 2.94 | ||||
MCRB | Seres Therapeutics | 2.33 | ||||
SRZN | Surrozen | 1.44 | ||||
SLS | Sellas Life | 1.16 | ||||
FBRX | Forte Biosciences | 0.52 | ||||
KTTA | Pasithea Therapeutics | 0.75 | ||||
INKT | Mink Therapeutics | 1.59 | ||||
PLX | Protalix Biotherapeutics | 1.64 | ||||
ALVR | Allovir | 2.17 | ||||
MIST | Milestone Pharmaceuticals | 3.23 | ||||
ONCY | Oncolytics Biotech | 3.57 | ||||
SCPH | Scpharmaceuticals | 3.63 | ||||
RVPH | Reviva Pharmaceuticals | 5.78 | ||||
EYPT | Eyepoint Pharmaceuticals | 6.05 | ||||
CADL | Candel Therapeutics | 31.12 |
Complementary Tools for BeyondSpring Stock analysis
When running BeyondSpring's price analysis, check to measure BeyondSpring's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeyondSpring is operating at the current time. Most of BeyondSpring's value examination focuses on studying past and present price action to predict the probability of BeyondSpring's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeyondSpring's price. Additionally, you may evaluate how the addition of BeyondSpring to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Stocks Directory Find actively traded stocks across global markets | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |